FDA Recommends Approval of Immucor's BeadChip Test
News Mar 19, 2014
Immucor's HEA test, which received CE Mark in July 2010 and is commercially available in Europe and other international markets, is currently available for Research Use Only in the United States. The HEA BeadChip product is an in vitro diagnostic test and is Immucor's core molecular test for extended typing of red blood cell antigens from a DNA sample. The product is designed to predict the phenotypes of the Rh (C,c,E,e), Kell (K, k, Kpa, Kpb, Jsa, Jsb), Duffy, Kidd, MNS, Lutheran, Dombrock (Doa, Dob, Hy, Jo), Landsteiner-Wiener, Diego, Colton, and Scianna blood group systems. The test is also designed to detect a mutation (HgbS 173 A > T) in the Beta Globin gene. More than 700,000 tests have been processed with Immucor's HEA assay worldwide.
"We are pleased with the outcome of today's BPAC meeting for our HEA BeadChip product, which represents the first molecular immunohematology test to be accepted for review by FDA," stated Joanne Spadoro, PhD, Immucor's Chief Scientific Officer and Vice President of Research and Development. "Molecular methods are intended to provide additional information regarding the composition of donor and patient blood, which may result in better matches, especially for multi-transfused patients, such as those suffering from cancer and sickle cell disease."
Immucor submitted its Pre-Market Approval (PMA) application to the FDA in June 2013 for the HEA Molecular BeadChip Test. The FDA will take into account the BPAC's advice in making its decision on whether to approve the HEA BeadChip Test for blood group typing in the United States. The Company expects a decision on approval later this year.
The BPAC reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood, products derived from blood and serum or biotechnology that are intended for use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which the FDA has regulatory responsibility, and advises the Commissioner of Food and Drugs of its findings.
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.
Automated Robotic Device Enables Faster Blood TestingNews
Rutgers researchers have created an automated blood drawing and testing device that provides rapid results, potentially improving the workflow in hospitals and other health-related institutions to allow health care practitioners to spend more time treating patients.READ MORE
New Method to Quickly and Accurately Detect InfectionsNews
A new study by UTSA researchers describes a method that could show quickly and accurately whether a person has been infected with harmful bacteria or other pathogens.READ MORE
Comments | 0 ADD COMMENT
International Conference on Central Nervous System and Therapeutics
Nov 12 - Nov 14, 2018